Determine Effect of Enzalutamide (MDV3100) on the Androgen Signaling Pathway in Correlation With the Anti-tumor Effects of Enzalutamide

• Status: Completed
• Trial end date: 2013-08-31
• Target enrollment: 0
• Participant gender: Male

Summary

This study is being conducted to determine the effect of enzalutamide on the androgen signaling pathway in correlation with the anti-tumor effects of enzalutamide to identify potential predictors of response or resistance to therapy.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Medivation, Inc.; Pfizer
• Collaborators: Astellas Pharma Inc; Medivation LLC, a wholly owned subsidiary of Pfizer Inc.

Criteria

Inclusion Criteria:

• Confirmed prostate cancer

• Presence of metastatic disease to the bone

• Ongoing androgen deprivation therapy

Exclusion Criteria:

• Severe concurrent disease

• Metastases in the brain